Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental combo targets tough cancers

NCT ID NCT03184870

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called BMS-813160, given together with chemotherapy or the immunotherapy nivolumab (Opdivo), in 332 people with advanced colorectal or pancreatic cancer. The main goals were to check safety, side effects, and how the body processes the drug, while also looking for early signs that the tumors shrink. The trial has been completed, and results will help decide if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BMS-813160 (an experimental drug) combined with chemotherapy (gemcitabine, nab-paclitaxel, 5-FU, leucovorin, irinotecan) or nivolumab (Opdivo)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced colorectal or pancreatic cancer.
What could go wrong
This is an early-phase trial focused on safety and dosing, so it is not yet known if the combination works better than existing treatments. Side effects from the drug combinations could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

332 people

The number who actually took part.

Started

Aug 2017

Finished

Jun 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Must have metastatic colorectal or pancreatic cancer * Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 * Ability to swallow pills or capsules * Required to undergo mandatory pre and on-treatment biopsies * Adequate marrow function * Adequate other organ functions * Ability to comply with study visits, treatment, procedures, pharmacokinetic (PK) and pharmacodynamic (PD) sample collection, and required study follow-up Exclusion Criteria: * Histology other than adenocarcinoma (neuroendocrine or acinar cell) * Suspected, known, or central nervous system (CNS) metastases (Imaging required only if participants are symptomatic) * Active, known or suspected autoimmune disease * Condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration * Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity * Prior treatment with cysteine-cysteine chemokine receptor 2 (CCR2) and/or cysteine-cysteine chemokine receptor 5 (CCR5) inhibitors, programmed death-1 receptor (PD-1), programmed death-ligand 1 \[PD(L)-1\] or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies * History of allergy to study treatments or any of its components of the study arm that participant is enrolling Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Pancreatic cancer

Contacts and locations

Locations

  • Local Institution - 0001

    Toronto, Ontario, M5G 1X6, Canada

  • Local Institution - 0002

    Los Angeles, California, 90033, United States

  • Local Institution - 0003

    Birmingham, Alabama, 35249, United States

  • Local Institution - 0004

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 0005

    Baltimore, Maryland, 21287, United States

  • Local Institution - 0007

    Heidelberg, 69120, Germany

  • Local Institution - 0012

    Ottawa, Ontario, K1H 8L6, Canada

  • Local Institution - 0013

    Edmonton, Alberta, T6G 1Z2, Canada

  • Local Institution - 0014

    Philadelphia, Pennsylvania, 19104, United States

  • Local Institution - 0015

    Aurora, Colorado, 80045, United States

  • Local Institution - 0016

    Salt Lake City, Utah, 84112, United States

  • Local Institution - 0017

    New York, New York, 10065, United States

  • Local Institution - 0018

    Washington D.C., District of Columbia, 20007, United States

  • Local Institution - 0020

    Philadelphia, Pennsylvania, 19107, United States

  • Local Institution - 0021

    Cleveland, Ohio, 44195, United States

  • Local Institution - 0022

    Dresden, 01307, Germany

  • Local Institution - 0023

    St Louis, Missouri, 63110, United States

  • Local Institution - 0024

    Rochester, New York, 14642, United States

  • Local Institution - 0025

    Los Angeles, California, 90033, United States

  • Local Institution - 0026

    Phoenix, Arizona, 85054, United States

  • Local Institution - 0027

    Rochester, Minnesota, 55905-0001, United States

  • Local Institution - 0028

    Clayton, Victoria, 0, Australia

  • Local Institution - 0030

    Majadahonda - Madrid, 28222, Spain

  • Local Institution - 0031

    Barcelona, 08003, Spain

  • Local Institution - 0032

    Madrid, 28046, Spain

  • Local Institution - 0033

    Boston, Massachusetts, 02114, United States

  • Local Institution - 0034

    Nashville, Tennessee, 37203, United States

  • Local Institution - 0037

    Allentown, Pennsylvania, 18103, United States

  • Local Institution - 0038

    Nashville, Tennessee, 37232, United States

  • Local Institution - 0039

    Hattiesburg, Mississippi, 39401, United States

  • Local Institution - 0041

    Orange, California, 92868-3201, United States

  • Local Institution - 0042

    Charlottesville, Virginia, 22908, United States

  • Local Institution - 0044

    Cleveland, Ohio, 44106-5055, United States

  • Local Institution - 0045

    Charleston, South Carolina, 29425, United States

  • Local Institution - 0046

    Charlotte, North Carolina, 28204, United States

  • Local Institution - 0047

    St. Petersburg, Florida, 33705, United States

  • Local Institution - 0048

    Brooksville, Florida, 34613, United States

  • Local Institution - 0049

    Leuven, 3000, Belgium

  • Local Institution - 0050

    Brussels, 1200, Belgium

  • Local Institution - 0051

    Edegem, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.